Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedSep 23, 2015HCG 625 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1515-2015Class IITerminatedSep 23, 2015HCG 625 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1514-2015Class IITerminatedSep 23, 2015HCG 625 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1513-2015Class IITerminatedSep 23, 2015HCG 1,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1512-2015Class IITerminatedSep 23, 2015HCG 2,500 IU/ml + Methylcobalamin 500 mcg/mlLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1511-2015Class IITerminatedSep 23, 2015HCG 1,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1510-2015Class IITerminatedSep 23, 2015HCG 1,100 IU/ml + Methylcobalamin 0.5 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1509-2015Class IITerminatedSep 23, 2015HCG 1,000 IU/ml + MIC B-12 InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1508-2015Class IITerminatedSep 23, 2015HCG 1,000 IU/ml + Methylcobalamin 1 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1507-2015Class IITerminatedSep 23, 2015HCG 1,000 IU/ml + Methylcobalamin 0.5 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1506-2015Class IITerminatedSep 23, 2015HCG 1,000 IU/ml + Methylcobalamin 0.05 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1505-2015Class IITerminatedSep 23, 2015HCG 1,000 IU/ml + Hydroxocobalamin 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1504-2015Class IITerminatedSep 23, 2015Glutathione 200 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1503-2015Class IITerminatedSep 23, 2015Folic Acid 5 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1502-2015Class IITerminatedSep 23, 2015Fentanyl 8Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1501-2015Class IITerminatedSep 23, 2015Fentanyl 7Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1500-2015Class IITerminatedSep 23, 2015Fentanyl 500 mcg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1499-2015Class IITerminatedSep 23, 2015Fentanyl 5Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1498-2015Class IITerminatedSep 23, 2015Fentanyl 5Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1497-2015Class IITerminatedSep 23, 2015Fentanyl 5Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1496-2015Class IITerminatedSep 23, 2015Fentanyl 5Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1495-2015Class IITerminatedSep 23, 2015Fentanyl 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1494-2015Class IITerminatedSep 23, 2015Fentanyl 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1493-2015Class IITerminatedSep 23, 2015Fentanyl 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1492-2015Class IITerminatedSep 23, 2015Fentanyl 17Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1491-2015Class IITerminatedSep 23, 2015Fentanyl 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1490-2015Class IITerminatedSep 23, 2015Fentanyl 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1489-2015Class IITerminatedSep 23, 2015Fentanyl 950 mcg/ml + Bupivacaine 5 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1488-2015Class IITerminatedSep 23, 2015Fentanyl 8Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1487-2015Class IITerminatedSep 23, 2015Fentanyl 7Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1486-2015Class IITerminatedSep 23, 2015Fentanyl 4Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1485-2015Class IITerminatedSep 23, 2015Fentanyl 3Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1484-2015Class IITerminatedSep 23, 2015Fentanyl 20Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1483-2015Class IITerminatedSep 23, 2015Fentanyl 15Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1482-2015Class IITerminatedSep 23, 2015Fentanyl 100 mcg/ml +Clonidine 400 mcg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1481-2015Class IITerminatedSep 23, 2015Fentanyl 10Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1480-2015Class IITerminatedSep 23, 2015Estradiol Valerate 40 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1479-2015Class IITerminatedSep 23, 2015Estradiol Valerate 20 mg/ml Injectable ml Multi-Dose VialLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1478-2015Class IITerminatedSep 23, 2015Estradiol Cypionate 5mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1477-2015Class IITerminatedSep 23, 2015Estradiol 8 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1476-2015